Skip to main content
. 2023 Jan 6;26:100573. doi: 10.1016/j.lanepe.2022.100573

Fig. 2.

Fig. 2

Overall survival in systemically treated patients diagnosed with metachronous HR+/HER2− ABC per period of diagnosis. mOS, median overall survival; CI, confidence interval.